PDCD1 and neoplasm: Recently, a phase I, open-label, multi-center study further characterized the anti-tumor effects of LNS8801 alone and in combination with immunotherapy (pembrolizumab, an anti-PD-1 antibody) in patients with solid tumors or lymphoma (NCT04130516).